Furthermore, response patients demonstrated enhanced signaling in immune-regulating pathways, such as TNF and CXCL, indicating that CD52 + DCs play a key role in modulating immune responses and shaping the tumor microenvironment (Fig. S5f, g). This evidence concerns the gene TNF and neoplasm.